Fast Track Initiative

RegCell is focused on developing innovative therapies for autoimmune diseases and cancer by enhancing or regulating the immune system. The company specializes in creating cell therapies that aim to address significant unmet medical needs. By returning regulatory T cells to the patient and activating them in vitro, RegCell seeks to provide effective treatment options for individuals suffering from these challenging conditions. Through its novel approach, the company aims to improve patient outcomes and address the complexities associated with autoimmune disorders and cancer.

Neusignal Therapeutics is a medical company focused on developing therapeutic medicines for dementia and various psychiatric illnesses. The company specializes in the research and development of small molecule drugs aimed at addressing brain diseases and overcoming challenges associated with central nervous system disorders. By concentrating on innovative therapeutic agents, Neusignal Therapeutics seeks to improve the quality of life for patients suffering from these conditions, aiming to resolve a range of issues related to brain health.

Medii, Ltd. is a Tokyo-based company that specializes in developing an e-consulting platform aimed at addressing the shortage of medical specialists in community healthcare. Founded in 2020, Medii offers online specialist consultation services that facilitate medical treatment through e-consulting and e-opinion. The platform helps to eliminate clinical questions and concerns by providing on-site consulting to medical institutions, leveraging the expertise of experienced doctors. This approach enables clinics and patients to access necessary medical assistance in areas where specialist resources are limited.

A10 Lab Inc. is a Tokyo-based company founded in 2016 that specializes in developing a self-improvement mobile application aimed at enhancing users' well-being through habit formation. The application employs a team-based approach, allowing users to form groups of five, fostering collaboration and accountability among participants. Through gamification and social encouragement, the platform helps individuals establish new routines and develop skills that contribute to their personal growth. A10 Lab's innovative solution not only aims to improve individual happiness but also enhances user engagement, ultimately benefiting businesses by increasing customer lifetime value. The app, known as 'Min Chale,' has received recognition on Google Play for its effectiveness in promoting positive behavior change.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

CellFiber Co., Ltd., founded in 2015 and headquartered in Tokyo, Japan, specializes in the research, development, production, and sale of cell-laden soft materials. The company focuses on cell culture technology and offers support tools for drug discovery, primarily aimed at biopharmaceutical development. CellFiber has developed a unique cell culture platform technology that facilitates efficient bio-manufacturing solutions, enhancing cell and gene therapy applications. This technology aims to increase yields and product quality while ensuring the stability, predictability, reproducibility, and scalability of cell production. By streamlining the mass production process of cells, CellFiber enables clients to reduce costs and timelines, ultimately supporting their transition from research to clinical use.

AIRNA is a biotech company that is pioneering RNA editing therapies to improve the health of individuals suffering from both rare and common ailments.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

Varinos Inc. is a clinical testing company based in Tokyo, Japan, founded in 2017. It specializes in genomic testing and continuous clinical sequencing services, offering innovative solutions such as endometrial microbiome testing and the analysis of intrauterine flora. By leveraging next-generation sequencing technology, Varinos partners with medical institutions to provide advanced contract analysis services. The company's genome analysis technology enables the detection of microscopic amounts of bacteria, facilitating the examination and diagnosis of genetic abnormalities in embryos prior to pregnancy. This approach aims to alleviate both physical and mental burdens for women seeking reproductive health solutions.

reverSASP Therapeutics is focused on developing innovative drugs aimed at treating aging-related diseases by targeting senescent cells. The company leverages its deep understanding of the biology underlying these conditions, particularly the Senescence-associated secretory phenotype (SASP), to create therapeutic solutions. By addressing the challenges posed by declining birthrates and an aging population, reverSASP Therapeutics aims to extend healthy life expectancy and improve the quality of life for older individuals. Its research emphasizes the unique properties of inflammatory senescent cells, which are linked to various age-related diseases, positioning the company as a key player in the field of longevity and healthspan enhancement.

MediPhone, Inc. is a company based in Minato, Japan, founded in 2014, that specializes in medical interpretation services aimed at overcoming language barriers in healthcare. The company offers a range of services including telephone and video medical interpretation, a medical translation application, and the dispatch of interpreters for advanced treatments and medical checkups. Additionally, MediPhone provides assistance with medical certificates, consent forms, and hospitalization guidance, ensuring that clients can access healthcare services seamlessly, regardless of language differences. Through its comprehensive offerings, MediPhone facilitates improved communication between medical personnel and patients, enhancing the overall healthcare experience.

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

A10 Lab Inc. is a Tokyo-based company founded in 2016 that specializes in developing a self-improvement mobile application aimed at enhancing users' well-being through habit formation. The application employs a team-based approach, allowing users to form groups of five, fostering collaboration and accountability among participants. Through gamification and social encouragement, the platform helps individuals establish new routines and develop skills that contribute to their personal growth. A10 Lab's innovative solution not only aims to improve individual happiness but also enhances user engagement, ultimately benefiting businesses by increasing customer lifetime value. The app, known as 'Min Chale,' has received recognition on Google Play for its effectiveness in promoting positive behavior change.

Fast Doctor is a medical consultation service that specializes in providing after-hours support for emergency visits. The company enables patients to access essential emergency care during nights and holidays, offering services such as triage, medical examinations, prescriptions, and home settlement. By facilitating prompt access to emergency medical services, Fast Doctor helps alleviate pressure on ambulance and emergency care systems, ensuring that patients receive timely assistance when they need it most.

Braizon Therapeutics, Inc. is a Tokyo-based company focused on the research and development of innovative drug delivery technologies aimed at treating central nervous system disorders. Founded in 2015, the company leverages collaborative research from prominent academics, including Professor Kazunori Kataoka and Professor Takanori Yokota, to create methodologies that facilitate the delivery of therapeutic drugs across the blood-brain barrier. By developing new drugs, diagnostics, and life science reagents, Braizon Therapeutics seeks to address the challenges associated with treating incurable neuronal diseases, ultimately enhancing the effectiveness of therapies for patients suffering from these conditions.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

RIN Institute Inc. is a bio-venture company based in Tokyo, Japan, focused on the research and development of antibody-based medicines and external diagnostic drugs. Founded in 2016, RIN Institute specializes in creating innovative therapeutic solutions for cancer treatment, including drugs specifically designed for breast and ovarian cancers. By developing antibody seeds, the company aims to enhance the efficacy of cancer therapeutics and diagnostics, ultimately improving recovery prospects for patients. Through its commitment to advancing medical science, RIN Institute seeks to contribute significantly to the field of oncology.

LUCA Science Inc. is a biotechnology company based in Japan that focuses on developing innovative mitochondrial therapies aimed at restoring bioenergetics in damaged tissues and organs. Utilizing its patented iMIT technology, the company creates a platform that delivers functional mitochondria to affected areas, potentially boosting cellular energy and normalizing physiological functions. This approach has the potential to address various unmet medical needs by employing mitochondria as biopharmaceutical agents, marking a significant advancement in the treatment of conditions related to impaired cellular energy production. LUCA Science is dedicated to improving disease management by enhancing mitochondrial activity and stability.

Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

Mental Health Technologies is a company that provides standard measures to maintain the mental health of employees, which is one of the foundations of health management.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

Fast Doctor is a medical consultation service that specializes in providing after-hours support for emergency visits. The company enables patients to access essential emergency care during nights and holidays, offering services such as triage, medical examinations, prescriptions, and home settlement. By facilitating prompt access to emergency medical services, Fast Doctor helps alleviate pressure on ambulance and emergency care systems, ensuring that patients receive timely assistance when they need it most.

Cytlimic Inc. is a biotechnology company based in Japan that focuses on the development of immunotherapy products, particularly cancer peptide vaccines. Founded in December 2016, the company specializes in the clinical trials and nonclinical testing of these vaccines, along with development and stability testing for investigational use. Cytlimic's innovative products are designed to activate the immune system to target and attack cancer cells, aiming to improve treatment outcomes while allowing patients to maintain a high quality of life during their therapy. By leveraging advanced knowledge in cancer immunology, Cytlimic seeks to provide effective solutions for cancer treatment.

PuREC is a biotechnology company focused on developing culture technology to enhance the efficacy of medical treatments. The company's innovative approach involves rapidly evolving cell therapies and mesenchymal stem cell therapies. PuREC's technology is particularly applied in two critical areas: addressing hypophosphatasia, a rare bone-formation deficiency in newborns, and treating spinal canal stenosis, which is caused by disc herniation in the spine. By leveraging advanced therapeutic techniques, PuREC aims to empower clients in their fight against various diseases and contribute to advancements in transplantation medicine.

RIN Institute Inc. is a bio-venture company based in Tokyo, Japan, focused on the research and development of antibody-based medicines and external diagnostic drugs. Founded in 2016, RIN Institute specializes in creating innovative therapeutic solutions for cancer treatment, including drugs specifically designed for breast and ovarian cancers. By developing antibody seeds, the company aims to enhance the efficacy of cancer therapeutics and diagnostics, ultimately improving recovery prospects for patients. Through its commitment to advancing medical science, RIN Institute seeks to contribute significantly to the field of oncology.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

Veldt Inc. is a Tokyo-based company that specializes in developing wearable technology, particularly luxury smartwatches designed to enhance daily life. Founded in 2012, Veldt offers a range of products under the VELDT brand, including the innovative VELDT SERENDIPITY smartwatch, which combines analog design with smartphone connectivity. This device features a transparent display that provides users with essential data while promoting a lifestyle that encourages exploration beyond screen time. The company sells its products through physical stores in Japan and offers online sales internationally. With a focus on functional design and the Internet of Things, Veldt aims to create a positive impact on both individual users and society by integrating technology into everyday routines in a meaningful way.

MediPhone, Inc. is a company based in Minato, Japan, founded in 2014, that specializes in medical interpretation services aimed at overcoming language barriers in healthcare. The company offers a range of services including telephone and video medical interpretation, a medical translation application, and the dispatch of interpreters for advanced treatments and medical checkups. Additionally, MediPhone provides assistance with medical certificates, consent forms, and hospitalization guidance, ensuring that clients can access healthcare services seamlessly, regardless of language differences. Through its comprehensive offerings, MediPhone facilitates improved communication between medical personnel and patients, enhancing the overall healthcare experience.

PENTAS Inc., founded in 2015 and based in Tokyo, Japan, specializes in the development of medical analysis software and devices. The company focuses on creating innovative solutions for medical equipment, particularly in the area of cerebral aneurysm fluid analysis and intracranial stents. As a subsidiary of Allm Inc., PENTAS is dedicated to advancing medical technology to improve patient outcomes.

Mental Health Technologies is a company that provides standard measures to maintain the mental health of employees, which is one of the foundations of health management.

Yukashikado Inc. is a Tokyo-based company founded in 2013 that specializes in personal nutrition testing products. The company offers at-home nutrition testing solutions that analyze various nutrients, including proteins, vitamins, minerals, and oxidative stress, using urine samples. These tests allow individuals to evaluate nutritional deficiencies and excesses, with results accessible through personal computers and smartphones. By providing an easy way to monitor nutritional intake and improvements, Yukashikado supports individuals in managing their health through personalized nutrition. The company sells its products online, catering to a growing demand for accessible health monitoring tools.

Braizon Therapeutics, Inc. is a Tokyo-based company focused on the research and development of innovative drug delivery technologies aimed at treating central nervous system disorders. Founded in 2015, the company leverages collaborative research from prominent academics, including Professor Kazunori Kataoka and Professor Takanori Yokota, to create methodologies that facilitate the delivery of therapeutic drugs across the blood-brain barrier. By developing new drugs, diagnostics, and life science reagents, Braizon Therapeutics seeks to address the challenges associated with treating incurable neuronal diseases, ultimately enhancing the effectiveness of therapies for patients suffering from these conditions.

Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

CellBank Corp. is a Tokyo-based company founded in 2004 that specializes in cell storage, regenerative medical technology, and the cosmetics sector. The company operates within the framework of regulations governing the safety of regenerative medicine, focusing on innovative solutions in the field. CellBank is dedicated to advancing technologies that support both medical and cosmetic applications, positioning itself as a key player in the intersection of these industries.

RIN Institute Inc. is a bio-venture company based in Tokyo, Japan, focused on the research and development of antibody-based medicines and external diagnostic drugs. Founded in 2016, RIN Institute specializes in creating innovative therapeutic solutions for cancer treatment, including drugs specifically designed for breast and ovarian cancers. By developing antibody seeds, the company aims to enhance the efficacy of cancer therapeutics and diagnostics, ultimately improving recovery prospects for patients. Through its commitment to advancing medical science, RIN Institute seeks to contribute significantly to the field of oncology.

NB Health Laboratory Co. Ltd. is a biotechnology company based in Kawaguchi, Japan, focused on the research and development of innovative drugs primarily targeting respiratory diseases, chronic inflammation, and infectious diseases. The company provides a research platform for screening small compounds in vitro and offers functional monoclonal antibodies. It engages in contract research, co-development, and licensing activities, and has developed DAP Kinase inhibitors aimed at addressing stroke and heart diseases. Additionally, NB Health Laboratory conducts research programs related to chronic obstructive pulmonary disease (COPD), aneurysms, and skin wrinkles, as well as drug and functional monoclonal antibody screening programs. Their products are designed for the treatment of vascular diseases, including atherosclerosis and stroke, as well as other conditions such as diabetes-related vascular disorders, COPD, and sleep disorders.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

Veldt Inc. is a Tokyo-based company that specializes in developing wearable technology, particularly luxury smartwatches designed to enhance daily life. Founded in 2012, Veldt offers a range of products under the VELDT brand, including the innovative VELDT SERENDIPITY smartwatch, which combines analog design with smartphone connectivity. This device features a transparent display that provides users with essential data while promoting a lifestyle that encourages exploration beyond screen time. The company sells its products through physical stores in Japan and offers online sales internationally. With a focus on functional design and the Internet of Things, Veldt aims to create a positive impact on both individual users and society by integrating technology into everyday routines in a meaningful way.

Veldt Inc. is a Tokyo-based company that specializes in developing wearable technology, particularly luxury smartwatches designed to enhance daily life. Founded in 2012, Veldt offers a range of products under the VELDT brand, including the innovative VELDT SERENDIPITY smartwatch, which combines analog design with smartphone connectivity. This device features a transparent display that provides users with essential data while promoting a lifestyle that encourages exploration beyond screen time. The company sells its products through physical stores in Japan and offers online sales internationally. With a focus on functional design and the Internet of Things, Veldt aims to create a positive impact on both individual users and society by integrating technology into everyday routines in a meaningful way.

EdiGENE Japan, now known as Modalis Therapeutics Corporation, is an emerging biotechnology company based in Tokyo, Japan. Founded in 2016, it specializes in the research and development of innovative therapeutics aimed at addressing serious genetic disorders. The company utilizes its proprietary CRISPR-GNDM technology, which allows for locus-specific modulation of gene expression and histone modification without the necessity for double-stranded DNA cleavage or traditional gene editing techniques. Modalis Therapeutics has established a solid intellectual property foundation, including licenses from the University of Tokyo, to support its focus on developing treatments for orphan genetic diseases and other unmet medical needs.

HanaVax is a drug discovery venture that develops next-generation nasal vaccines.In addition to systemic immunity, nasal vaccines that can induce mucosal immunity to the respiratory mucosa, which is the entry point for pathogens, are considered the most effective vaccines for respiratory infections. Nanogel is a cholesterol pullulan that has already been confirmed to be safe in humans, and can induce mucosal immunity more effectively by cationization. Induction of both systemic and mucosal immunity by effectively delivering vaccine and adjuvant to immunocompetent cells by encapsulating the vaccine antigen alone or in a nanogel with an adjuvant and introducing it into the mucosa via nasal administration It is a system that can do it. Vaccine adjuvant encapsulated in cationized nanogels is easily taken up by epithelial cells. The cationized nanogel acts as an artificial molecular chaperone to maintain the structure of the vaccine, efficiently delivering vaccine antigens to dendritic cells below the basement membrane of epithelial cells, effectively presenting the antigens to the immune system, and generating a strong immune response. Induces both mucosal and systemic systems. In other words, the cationized nanogel nasal delivery system elicits the two-stage protective immunity of humans and prevents the development of infectious diseases.

NIL is a bio-tech company that develops innovative and functional ultrafine particle technology based on many years of research experience.

Mental Health Technologies is a company that provides standard measures to maintain the mental health of employees, which is one of the foundations of health management.

NIL provides services including planning, development, maintenance, and sales of various software development tools, research and development linked to software engineering, and more. It also offers services like system and software development, maintenance, sales, and consultation. It offers software tools for use with things like automotive and medical systems.

ReasonWhy Inc. is a Japan-based company founded on July 7, 2011, that specializes in healthcare IT services. The company offers four main services: Whytlink, a social network designed for doctors; Findme, an online second-opinion service that connects patients with doctors from the Whytlink network; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers in Japan; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy seeks to enhance communication and information sharing within the medical community while improving patient access to healthcare resources.

Cytlimic Inc. is a biotechnology company based in Japan that focuses on the development of immunotherapy products, particularly cancer peptide vaccines. Founded in December 2016, the company specializes in the clinical trials and nonclinical testing of these vaccines, along with development and stability testing for investigational use. Cytlimic's innovative products are designed to activate the immune system to target and attack cancer cells, aiming to improve treatment outcomes while allowing patients to maintain a high quality of life during their therapy. By leveraging advanced knowledge in cancer immunology, Cytlimic seeks to provide effective solutions for cancer treatment.

NB Health Laboratory Co. Ltd. is a biotechnology company based in Kawaguchi, Japan, focused on the research and development of innovative drugs primarily targeting respiratory diseases, chronic inflammation, and infectious diseases. The company provides a research platform for screening small compounds in vitro and offers functional monoclonal antibodies. It engages in contract research, co-development, and licensing activities, and has developed DAP Kinase inhibitors aimed at addressing stroke and heart diseases. Additionally, NB Health Laboratory conducts research programs related to chronic obstructive pulmonary disease (COPD), aneurysms, and skin wrinkles, as well as drug and functional monoclonal antibody screening programs. Their products are designed for the treatment of vascular diseases, including atherosclerosis and stroke, as well as other conditions such as diabetes-related vascular disorders, COPD, and sleep disorders.

ReasonWhy Inc. is a Japan-based company founded on July 7, 2011, that specializes in healthcare IT services. The company offers four main services: Whytlink, a social network designed for doctors; Findme, an online second-opinion service that connects patients with doctors from the Whytlink network; WhytPlot, a big-data analysis tool aimed at pharmaceutical manufacturers in Japan; and yourHospital, a search engine that helps users find specialist hospitals. Through these services, ReasonWhy seeks to enhance communication and information sharing within the medical community while improving patient access to healthcare resources.

Braizon Therapeutics, Inc. is a Tokyo-based company focused on the research and development of innovative drug delivery technologies aimed at treating central nervous system disorders. Founded in 2015, the company leverages collaborative research from prominent academics, including Professor Kazunori Kataoka and Professor Takanori Yokota, to create methodologies that facilitate the delivery of therapeutic drugs across the blood-brain barrier. By developing new drugs, diagnostics, and life science reagents, Braizon Therapeutics seeks to address the challenges associated with treating incurable neuronal diseases, ultimately enhancing the effectiveness of therapies for patients suffering from these conditions.

AccuRna, Inc. is a biotechnology company based in Tokyo, Japan, specializing in the research and development of nucleic acid-based drugs through advanced drug delivery systems. Founded in 2015, the company aims to advance therapeutic innovation by utilizing its robust drug delivery system platform to provide effective treatments for refractory diseases, which currently lack cures. AccuRna focuses on developing technologies that facilitate the delivery of various nucleic acid therapeutics, including siRNA, ASO, miRNA, mRNA, and CRISPR-CAS. By ensuring safe and efficient delivery of these therapies, AccuRna endeavors to provide radical cures for patients worldwide suffering from challenging medical conditions.

PuREC is a biotechnology company focused on developing culture technology to enhance the efficacy of medical treatments. The company's innovative approach involves rapidly evolving cell therapies and mesenchymal stem cell therapies. PuREC's technology is particularly applied in two critical areas: addressing hypophosphatasia, a rare bone-formation deficiency in newborns, and treating spinal canal stenosis, which is caused by disc herniation in the spine. By leveraging advanced therapeutic techniques, PuREC aims to empower clients in their fight against various diseases and contribute to advancements in transplantation medicine.

CellSeed Inc. is a biotechnology company based in Tokyo, Japan, focused on developing regenerative medicine products primarily for markets in Japan and Europe. Founded in 2001, the company specializes in cell-sheet regenerative medicines, which include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart diseases, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for treating osteoarthritis. In addition to its product offerings, CellSeed also provides temperature-responsive cultureware, such as UpCell and RepCell, designed for cell-sheet engineering and collection, respectively. The company further supports the industry through contract development and manufacturing services.

BrightPath Biotherapeutics Co., Ltd. is a biopharmaceutical company based in Kurume, Japan, specializing in the development of innovative cancer immunotherapy drugs. The company is advancing its lead candidate, ITK-1, a cancer peptide vaccine currently in Phase III clinical trials for the treatment of prostate cancer. Additionally, BrightPath is developing GRN-1201, which is in Phase II trials for non-small cell lung cancer and Phase I trials for melanoma. The company also has research-stage products, including GRN-1301, a neoantigen targeting drug-resistant tumors in non-small cell lung cancer, and iPS-NKT, a therapy utilizing induced pluripotent stem cell-derived NKT cells. Founded in 2003, BrightPath Biotherapeutics aims to stimulate potent immune responses to tumor-associated antigens through its peptide vaccine technology.

ProbeX specializes in the development, manufacture, and distribution of molecular imaging technology. The company focuses on creating research tools that enhance molecular imaging capabilities, particularly in the context of drug discovery. In addition to its product offerings, ProbeX provides consulting services to support research initiatives in the field of molecular imaging. Through its innovative approach, ProbeX aims to advance the understanding of biological processes and improve outcomes in pharmaceutical research.

Japan Medical Information Research Institute focuses on the collection, analysis, and marketing of medical information. The organization provides consulting services to help clients understand and utilize medical data effectively. Through its expertise in medical information, the institute aims to enhance the decision-making processes within the healthcare sector.

CellSeed Inc. is a biotechnology company based in Tokyo, Japan, focused on developing regenerative medicine products primarily for markets in Japan and Europe. Founded in 2001, the company specializes in cell-sheet regenerative medicines, which include epithelial cell sheets for corneal and esophageal regeneration, regenerated cardiac patches for heart diseases, cell sheets for periodontal tissue regeneration, and regenerated cartilage sheets for treating osteoarthritis. In addition to its product offerings, CellSeed also provides temperature-responsive cultureware, such as UpCell and RepCell, designed for cell-sheet engineering and collection, respectively. The company further supports the industry through contract development and manufacturing services.

Chiome Bioscience Inc. is a Japanese biotechnology company founded in 2005, specializing in the research and development of innovative drug discovery technologies. The company is renowned for its ADLib System, a proprietary monoclonal antibody generation technology designed to facilitate drug discovery and development. Chiome offers a variety of services, including protein expression and purification, stable cell line generation, and antibody generation using advanced techniques. Its product pipeline features several therapeutic candidates targeting various cancers and diseases, such as ADCT-701 for liver cancer and CBA-1205 for multiple cancer types. Chiome collaborates with universities, research institutions, and pharmaceutical companies to advance its projects, including a partnership with Velabs Therapeutics focused on antibody discovery. With a strategic shift towards drug development following a merger in 2015, Chiome is committed to enhancing its clinical capabilities and increasing corporate value through innovative therapeutic solutions. The company is headquartered in Tokyo, Japan.